Avutometinib + Defactinib for Non-Small Cell Lung Cancer(RAMP202 Trial)

"As of now, the trial is recruiting from 30 different sites located across America. Notable cities include Saint Louis, Chattanooga and Hackensack among others. It would be wise to select a location closest you so as to reduce travel commitments for participants."

"This research, funded by Verastem Inc., requires 100 qualified individuals. It will be conducted at Washington University School of Medicine in Saint Louis and Chattanooga Oncology Hematology Assoc. in Chattanooga, New Jerseyt Washington University School of Medicine in Saint Louis and Chattanooga Oncology Hematology Assoc. in Chattanooga, New Jersey."

"This clinical trial has two main objectives. The primary goal is to measure efficacy over a 24-week period, while the secondary outcomes evaluate Overall Response Rate (ORR), Duration of Response (DOR) and Progression Free Survival (PFS). These metrics are assessed by investigator assessments such as Complete/Partial Remission or Disease Progression."

"Indeed, the clinicaltrials.gov portal shows that this trial is presently recruiting patients - it was initially posted on December 31st 2020 and last updated July 19th 2022. The study requires 100 participants to be recruited from 30 different sites."

"VS-6766 was initially examined by the ECOG-ACRIN Cancer Research Group in 2015. Presently, there are 9 active research projects and 7 completed trials that have been conducted regarding this medication – many of which occur within Saint Louis, MissouriN Cancer Research Group in 2015. Presently, there are 9 active research projects and 7 completed trials that have been conducted regarding this medication – many of which occur within Saint Louis, Missouri."

"Our team at Power evaluated the safety of VS-6766 to be a 2 due to its Phase 2 status. This indicates that there is some evidence backing the drug's security, but none confirming effectiveness."